MAPT and Alzheimer disease: Milestone advances in the development and evaluation of plasma (Aβ1–42 and neurofilament light concentrations) and CSF biomarkers (Aβ1–42, total-tau, p-tau concentrations) have also revolutionized the prospect of early diagnosis for AD (Hampel et al., 2018; Baldacci et al., 2020).